Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Prevnar 13 in Vaccine-Naive Older Infants and Children
NCT00452452Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2007
- Primary completion
- Mar 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Prevnar 13 in pneumococcal infection, sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination and Geometric Mean Antibody Concentration (GMC) After Vaccination. Started Jul 2007; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00452452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452452.